CHRS Coherus BioSciences Inc.

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on  following the conclusion of the live conference call.

Conference Call Information

When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call:

Please dial in 15 minutes early to ensure a timely connection to the call.

Webcast:

The press release with the second quarter 2024 financial results and related materials will be available at  before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at .

Disclosure Information

Coherus uses the  website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

Coherus Contact Information

Investors:

Jami Taylor, Head of Investor Relations for Coherus



EN
01/08/2024

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial...

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live c...

March 2, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: . A replay of the presentation will be available on this same website for approximately 90 days. 46th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Da...

February 23, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock –The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwriting discounts and ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common ...

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected t...

February 13, 2026 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common St...

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Offering ar...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch